The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
Open accessAbstract
Purpose: The long-term risk of prostate cancer–specific mortality (PCSM) after radical prostatectomy is poorly defined for patients treated in the era of widespread prostate-specific antigen (PSA) screening. Models that predict the risk of PCSM are needed for patient counseling and clinical trial design. Methods: A multi-institutional cohort of 12,677 patients treated with radical prostatectomy between 1987 and 2005 was analyzed for the risk of PCSM. Patient clinical information and treatment outcome was modeled using Fine and Gray competing risk regression analysis to predict PCSM. Results: Fifteen-year PCSM and all-cause mortality were 12% and 38%, respectively. The estimated PCSM ranged from 5% to 38% for patients in the lowest and highest quartiles of predicted risk of PSA-defined recurrence, based on a popular nomogram. Biopsy Gleason grade, PSA, and year of surgery were associated with PCSM. A nomogram predicting the 15-year risk of PCSM was developed, and the externally validated concordance index was 0.82. Neither preoperative PSA velocity nor body mass index improved the model's accuracy. Only 4% of contemporary patients had a predicted 15-year PCSM of greater than 5%. Conclusion: Few patients will die from prostate cancer within 15 years of radical prostatectomy, despite the presence of adverse clinical features. This favorable prognosis may be related to the effectiveness of radical prostatectomy (with or without secondary therapy) or the low lethality of screen-detected cancers. Given the limited ability to identify contemporary patients at substantially elevated risk of PCSM on the basis of clinical features alone, the need for novel markers specifically associated with the biology of lethal prostate cancer is evident.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“We were also unable to identify an association between BMI and PCSM, despite its reported association with PSA recurrence in surgical series,(32) and PCSM in population-based studies.(33) More recent year of surgery has been reported to be associated with an improved risk of PSA recurrence.”
ResultD'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074311 · Cited by 2,253
Self-citationSurrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Cited by
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citationThe Diagnosis and Treatment of Prostate Cancer: A Review
Litwin, M. S., & Tan, H.-J. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,435
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Self-citationPredicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
Eggener, S. E., Scardino, P. T., Walsh, P. C., Han, M., Partin, A. W., Trock, B. J., Feng, Z., Wood, D. P., Eastham, J. A., Yossepowitch, O., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.057 · Cited by 640
Self-citationHigh-risk prostate cancer—classification and therapy
Chang, A. J., Autio, K. A., Roach, M., & Scher, H. I. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.68 · Cited by 500
Soto-Perez-de-Celis, E., Li, D., Yuan, Y., Lau, Y. M., & Hurria, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30348-6 · Cited by 400
Karnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Boorjian, S. A., Karnes, R. J., Viterbo, R., Rangel, L. J., Bergstralh, E. J., Horwitz, E. M., Blute, M. L., & Buyyounouski, M. K. (2011) · Cancer · doi:10.1002/cncr.25900 · Cited by 272
Metadata
- Authors
- Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-10
- Volume
- 27
- Issue
- 26
- Pages
- 4300-4305
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102229192
- Cited by
- 419
- References
- 37
- FWCI
- 35.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.